Getein Biotech, Inc (China)

Getein Biotech, Inc. (stock code 603387) was established in March 2002 and is headquartered in Nanjing. In July 2017, the company went public on the main board of the Shanghai Stock Exchange. The company focuses on the research, development, production, sales, and service of in vitro diagnostic products. It has established eight technology platforms, including colloidal gold immunochromatography, fluorescence immunochromatography, biochemistry, chemiluminescence, blood cell analysis, hemostasis and thrombosis testing, molecular diagnostics, and diagnostic reagent materials. With a modern processing center, BSI ISO13485 quality management system certification, and CE certification, the company ensures the quality of its products and a complete industry chain layout. Its global marketing network, consisting of subsidiaries and offices around the world, enables the company's high-quality products to be sold in more than 120 countries and receive wide acclaim from domestic and international customers. Currently, the company holds more than 300 authorized patents and has over 1,120 registered independent product certificates domestically and internationally. These certificates cover various fields, including cardiovascular diseases, kidney injury, diabetes, pregnancy, infectious diseases, and tumors, and are widely used in medical institutions at all levels. In the future, while maintaining its leading position in point-of-care testing (POCT), the company will steadily expand into sectors such as biochemistry, chemiluminescence, blood cell analysis, coagulation, microbiological testing, molecular diagnostics, and laboratory automation solutions. It is committed to becoming an internationally competitive biotechnology company and contributing to the improvement of human health and medical standards.